Payton Nyvquest is Co-founder and CEO of Numinus, a for-profit psychedelic company based in Canada that empowers people to heal and be well through the development and delivery of safe, evidence-based psychedelic-assisted therapies. Payton has more than 15 years experience working in finance, investment and retail banking. He pivoted to the emerging psychedelics industry not long after ayuasahca helped him experience deep relief from a lifelong battle with chronic pain. At Numinus, he guides teams in strategy, innovation, research and clinic network expansion and is responsible for raising more than $70 million for Numinus in the past year.

Together we talked about the difference between a for-profit and nonprofit psychedelic organization, how he works in conjunction with MAPS, the Multidisciplinary Association for Psychedelic Studies (which is a non profit), how he sees psychedelic services intersecting with existing health care protocols in the united states, why Numinus is a publicly traded company, why he believes his company’s stock price will rise, and how being a father to a young child has influenced the direction his life has taken.